[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100369955":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":28,"locations":37,"responsibleParty":57,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":20,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":20,"enrollmentInfo":72,"targetDuration":20,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":40,"whyStopped":20,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University Hospital Muenster","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment (low-dose radiation therapy)","EXPERIMENTAL","Patients undergo low-dose radiation therapy with daily 2 Gy ad 20 Gy (ISRT with IMRT \\& IGRT).\n\nBlood draw for biomarker-analysis (at baseline visit\u002F after 4 Gy\u002F after 10 Gy \u002F after 20 Gy RT\u002F at 3 and 6 months after RT)",[13],"Radiation: Radiation Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Radiation Therapy","Low dose radiotherapy with 20 Gy (10x2Gy)",[9],null,[22,26],{"name":23,"affiliation":24,"role":25},"Prof. Dr. H. Th. Eich","Department of Radiation Oncology University Hospital Muenster","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":24,"role":25},"Priv. Doz. Dr. G. Reinartz",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":20,"email":33},"Gabriele Reinartz, MD (Priv. Doz.)","CONTACT","+492518347358","gabriele.reinartz@ukmuenster.de",{"name":35,"role":31,"phone":32,"phoneExt":20,"email":36},"Tina Fischer","tina.fischer@ukmuenster.de",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Department of Radiation Oncology","RECRUITING","Münster","North Rhine-Westphalia","48149","Germany","DE",{"type":47,"coordinates":48},"Point",[49,50],7.62571,51.96236,{"lat":50,"lon":49},[53,54],{"name":30,"role":31,"phone":32,"phoneExt":20,"email":33},{"name":55,"role":31,"phone":32,"phoneExt":20,"email":56},"Stephan Rehn, MD","stephan.rehn@ukmuenster.de",{"type":58,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[60],{"name":61,"class":62},"International Lymphoma Radiation Oncology Group (ILROG)","UNKNOWN","100369955","isrt-20-gy-for-indolent-localized-gastrointestinal-gi-lymphoma-100369955",false,"NCT04097067","ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma","Phase II Trial to Assess the Efficacy of Low Radiation Dose of 20 Gy for the Treatment of Marginal Zone Lymphoma or Follicular Lymphoma Stage I-II Localized in the Stomach or the Duodenum","Inclusion Criteria:\n\n* primary indolent gastric or duodenal lymphoma\n* pathology: marginal zone lymphoma (MZL) or follicular lymphoma (FL)\n* stage: clinical stage I or II (Ann Arbor classification)\n* H. pylori negative or antibiotic resistant lymphoma\n* IPI or FLIPI score low - high (0-4)\n* any size of tumor or affected lymph nodes\n* male or female with age ≥ 18 years\n* performance status ECOG 0 - 3\n* written informed consent by the patient\n\nExclusion Criteria:\n\n* prior radiation treatment of the gastrointestinal lymphoma\n* stage: clinical stage III or IV (Ann Arbor classification)-unability to understand the informed consent or unwillingness to participate in the study\n* severe comorbidity or organ dysfunction contraindicating the use of RT (liver cirrhosis Child-Pugh C, chronic obstructive pulmonary disease GOLD 4, heart insufficiency NYHA IV, dialysis dependent renal insufficiency, uncontrolled epilepsy)\n* known seropositivity for HIV\n* acute hepatitis B or C infection\n* chronic inflammatory bowel disease\n* prior malignant disease (exclusion: basalioma, non-metastasized solid tumor in constant remission diagnosed \\>3 years ago)\n* pregnancy or breastfeeding\n* active substance abuse or severely compromised compliance","ALL","18 Years",{"count":73,"type":74},83,"ESTIMATED","INTERVENTIONAL",[77],"NA","This trial studies the effectivity of low-dose radiation therapy with 10x2Gy for the treatment of patients with stage I-II stomach or duodenal Lymphoma (Marginal Zone or Follicular)",[80,81],"Follicular Lymphoma (Gastric or Duodenal)","Marginal Zone Lymphoma (Gastric or Duodenal)",[83,84,85,86,87,88,89,90,91,92,93],"Lymphoma","Lymphoma, B-Cell, Marginal Zone","Neoplasms by Histologic Type","Neoplasms","Lymphoproliferative Disorders","Lymphatic Diseases","Immunoproliferative Disorders","Immune System Diseases","Lymphoma, B-Cell","Lymphoma, Non-Hodgkin","Lymphoma, follicular","2024-08-26",{"date":96,"type":97},"2024-08-27","ACTUAL",{"date":99,"type":97},"2019-09-01",{"date":101,"type":74},"2025-08-31",{"name":5,"class":6},1]